According to Zhitong Finance App, Hanson Pharmaceuticals (03692) announced that on August 21, 2026, based on the positive results of the critical phase III trial ARTEMIS-008 of Ruikang rivoltamab (HS-20093) (this product), the product's indications for small cell lung cancer that failed platinum-containing treatment were included in the China National Drug Administration (NMPA) priority review and approval process.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.